For example, retrospective cohort studies have shown that incretin-based therapies involving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with diabetes have been associated with an increased risk of pancreatic cancer [58]. This evidence concerns the gene GLP1R and pancreatic neoplasm.